Day 1 Flexibility: I.V. or P.O.
In combination with other antiemetics, EMEND provides 5 days of protection in 3 daily doses.
- EMEND is given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 receptor antagonist. The recommended dosage includes EMEND (125 mg) on Day 1 followed by EMEND (80 mg) once daily on Days 2 and 3. EMEND for Injection (115 mg) may be substituted for EMEND 30 minutes before chemotherapy, on Day 1 only, as an infusion administered over 15 minutes.
- EMEND, in combination with other antiemetic agents, is indicated for prevention of:
- Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
- Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
EMEND is part of an antiemetic regimen containing:
In clinical trials, EMEND was given with ondansetron and dexamethasone.
Selected Important Risk Information
Caution: EMEND for Injection should not be mixed or reconstituted with solutions for which physical and chemical compatibility have not been established. EMEND for Injection is incompatible with any solutions containing divalent cations (eg, Ca2+, Mg2+), including Lactated Ringer's Solution and Hartmann's Solution.
The most frequent clinical adverse events reported in patients receiving EMEND for Injection were infusion site pain (7.6%), headache (3.0%), and infusion site induration (1.5%).
Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.
For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.
